Valuation: Immatics N.V.

Market Cap 93Cr 85Cr 78Cr 71Cr 133.12Cr 8.68TCr 138.37Cr 945.93Cr 373.92Cr 4.68TCr 348.46Cr 341.16Cr 15TCr P/E 2026 *
-2.83x
P/E 2027 * -2.9x
Enterprise Value 61Cr 55Cr 51Cr 46Cr 87Cr 5.67TCr 90Cr 618.26Cr 244.39Cr 3.06TCr 227.75Cr 222.98Cr 9.67TCr EV / Sales 2026 *
17.1x
EV / Sales 2027 * 21.4x
Free-Float
76.67%
Yield 2026 *
-
Yield 2027 * -
1 day-3.02%
1 week-8.82%
Current month-15.28%
1 month-9.36%
3 months-32.89%
6 months-42.56%
Current year-41.90%
1 week 5.95
Extreme 5.95
6.57
1 month 5.95
Extreme 5.95
7.95
Current year 5.95
Extreme 5.95
11.94
1 year 5.95
Extreme 5.95
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 8,63,060 0.6436%
18/03/26 Other

Chief Financial Officer

3,50,000 0.2611%
18/03/26 Other

Head of Human Resources

2,11,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-3.02%-8.82%-40.89%-29.72% 86Cr
-1.34%-3.09%+56.10%+68.83% 6.64TCr
+0.59%-1.83%+8.98%+90.01% 5.89TCr
+0.54%+0.45%+25.96%+87.77% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.72TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.64TCr
-1.76%-11.56%+126.44%+649.27% 3.52TCr
-0.17%-1.83%+82.46%+57.69% 3.27TCr
-1.69%-0.79%-40.58%+382.68% 2.67TCr
Average -1.17%-4.42%+26.66%+148.97% 4TCr
Weighted average by Cap. -0.85%-3.65%+34.06%+143.60%

Financials

2026 *2027 *
Net sales 3.52Cr 3.21Cr 2.97Cr 2.68Cr 5.05Cr 329.14Cr 5.25Cr 36Cr 14Cr 177.66Cr 13Cr 13Cr 560.99Cr 3.14Cr 2.86Cr 2.65Cr 2.39Cr 4.5Cr 293.42Cr 4.68Cr 32Cr 13Cr 158.37Cr 12Cr 12Cr 500.1Cr
Net income -30Cr -28Cr -26Cr -23Cr -43Cr -2.83TCr -45Cr -308.57Cr -121.97Cr -1.53TCr -113.67Cr -111.29Cr -4.83TCr -34Cr -31Cr -28Cr -26Cr -48Cr -3.15TCr -50Cr -343.16Cr -135.65Cr -1.7TCr -126.41Cr -123.76Cr -5.37TCr
Net Debt -32Cr -29Cr -27Cr -24Cr -46Cr -3.01TCr -48Cr -327.67Cr -129.52Cr -1.62TCr -120.71Cr -118.18Cr -5.12TCr -25Cr -23Cr -21Cr -19Cr -36Cr -2.37TCr -38Cr -257.87Cr -101.94Cr -1.28TCr -95Cr -93Cr -4.03TCr
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
721
Date Price Change Volume
18/26/18 $6.100 -3.02% 15,71,164
17/26/17 $6.290 +1.94% 31,64,202
16/26/16 $6.170 -3.44% 7,62,157
13/26/13 $6.390 -1.99% 5,86,386
12/26/12 $6.520 -2.54% 8,09,266
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.100USD
Average target price
16.03USD
Spread / Average Target
+162.76%
  1. Stock Market
  2. Stocks
  3. IMTX Stock